SGO survey offers snapshot of gynecologic oncology

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 7
Volume 19
Issue 7

The Society of Gynecologic Oncologists conducted a demographic and practice survey and found that their members are shifting away from private practice into salaried positions. The survey also found an increase in the number of group or multispecialty practices.

The Society of Gynecologic Oncologists conducted a demographic and practice survey and found that their members are shifting away from private practice into salaried positions. The survey also found an increase in the number of group or multispecialty practices.

"Gynecologic Oncology 2010: State of the Subspecialty" looked at changes in practice characteristics and patterns, workload activities, and liability. The survey can be obtained at www.sgo.org.

"The ability to compare and contrast the subspecialty's current climate with that of five years ago gives our profession a concrete idea to the trends in women's cancer care," said Daniel Clarke-Pearson, MD, SGO president. "The study's findings offer a real indication of practice workforce needs, what is required of today's gynecologic oncologist, and a road map for where the profession is heading in the future."

In other news, the society has published the third installment in its four-part series on cervical cancer. The white paper, entitled "Can the Barriers to HPV Vaccination in High-Risk Populations be Overcome?" identified populations of U.S. women at high risk for cervical cancer and evaluated the known reasons for existing outcomes disparities.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
Related Content